Jiangxi Synergy Pharmaceutical Co Ltd (300636.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE100002P83
Jiangxi Synergy Pharmaceutical Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 758.89 m CNY | 828.66 m CNY |
| Gross profit | 219.51 m CNY | 250.73 m CNY |
| Operating income | 111.40 m CNY | 126.62 m CNY |
| EBIT | 133.78 m CNY | 88.08 m CNY |
| Net income | 106.58 m CNY | 73.09 m CNY |
| Diluted EPS – continuing operations | 0.25 CNY | 0.17 CNY |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Jiangxi Synergy Pharmaceutical Co Ltd
Jiangxi Synergy Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and fine chemicals in China and internationally. The company offers API products for anti-epilepsy and pain treatment, anti-inflammatory, gastrointestinal, anti-hypertension, anti-gout, anti-diabetes, anti-thrombotic, urology, non-alcoholic steatohepatitis, idiopathic parkinsonism, hypolipidemic agents, migraine therapy, prostate cancer, endometriosis, anemia, atopic dermatitis, nervous system, digestive system, antipyretic analgesics and non-steroidal anti-inflammatory, anticoagulant, hypoglycemic drug, and antidepressant indications. It also provides intermediate products, including rivaroxaban, apixaban, empagliflozin, canagliflozin, ipragliflozin, mirabegron, vibegron, agomelatine, febuxostat, vildagliptin, vonoprazan fumarate, dabigatran etexilate mesylate, azilsartan base and medoxomil potassium, candesartan cilexetil, rimegepant, resmetirom, and opicapone. In addition, the company offers contract manufacturing organization (CMO) services, including production capacity, good manufacturing practice (GMP), regulatory support, research and development for process optimization and scale-up production, and environmental, health, and safety (EHS) management systems. It exports its products to Europe, the United States, Japan, and South Korea. Jiangxi Synergy Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Yichun, the People's Republic of China.
More stocks
- Lumosa Therapeutics Co. Ltd. (6535.TWO)
- Don Muang Tollway Public Company Limited (DMT.BK)
- Wanma Technology Co Ltd (300698.SZ)
- LAY-OUT Planning Consultants Co. Ltd. (300989.SZ)
- Isoenergy Ltd (ISO.TO)
- All for One Group (A1OS.DE)
- Consolidated Water Co. Ltd. (CWCO)
- Nanjing Inform Storage Equip (603066.SS)
- Oriental Kopi Holdings Berhad (0338.KL)
- Whitefield Industrials Ltd (WHF.AX)
- Suzhou Longjie Special Fiber Co Ltd (603332.SS)
- Ningbo Tianyi Medical Appliance Co. Ltd. (301097.SZ)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.